Accessibility statement

Medicare drug price negotiation in the US: Implications and unanswered questions

Friday 2 December 2022, 1.00PM to 2.00pm

Speaker(s): Sean D. Sullivan, University of Washington

Abstract: The U.S. is a relatively free-pricing market for pharmaceutical manufacturers to set list prices at product launch. Few drug price controls exist, and federal price negotiation as a policy has historically been politically untenable. After decades of debate on whether the federal government, specifically the Medicare program, should more actively manage drug prices, the

U.S. Congress passed legislation authorizing Medicare to directly negotiate prices with manufacturers. We discuss elements of the price negotiation provisions and comment on potential impacts on payers and the industry. While impacting only a few drugs each year in the beginning, price negotiation in the Medicare program will have secondary and longer-term effects in the US market and beyond. What is clear is that the Medicare market in the US for drugs will no longer be a free-pricing environment for the industry.

Join Zoom Meeting
https://york-ac-uk.zoom.us/j/91360167167?pwd=Q1R2MFIrKzdSd0N6R2JiM20rVVBzdz09

Meeting ID: 913 6016 7167
Passcode: 276016

Location: A019/020 and via Zoom (not recorded)

Who to contact

For more information on these seminars, contact:

Adrian Villasenor
Adrian Villasenor-Lopez
Dacheng Huo
Dacheng Huo

If you are not a member of University of York staff and are interested in attending the seminar, please contact Adrian Villasenor-Lopez or Dacheng Huo so that we can ensure we have sufficient space

CHE Seminar Programme

  • Friday 2 December
    Sean D. Sullivan, University of Washington

Map showing Location Details (PDF , 297kb)